Literature DB >> 27810993

Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients.

Elizabeth Margolskee1, Spencer Krichevsky2, Attilio Orazi1, Richard T Silver3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27810993      PMCID： PMC5394963          DOI： 10.3324/haematol.2016.153973

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  17 in total

1.  Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.

Authors:  Marco Pizzi; Richard T Silver; Ariella Barel; Attilio Orazi
Journal:  Mod Pathol       Date:  2015-08-14       Impact factor: 7.842

2.  Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

Authors:  Giovanni Barosi; Gunnar Birgegard; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Jean-Jacques Kiladjian; Eva Lengfelder; Mary Frances McMullin; Francesco Passamonti; John T Reilly; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood       Date:  2009-03-10       Impact factor: 22.113

Review 3.  Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Authors:  A M Vannucchi; E Antonioli; P Guglielmelli; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2008-05-22       Impact factor: 11.528

4.  Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials.

Authors:  Richard T Silver; Hans Carl Hasselbalch
Journal:  Hematology       Date:  2016-02-26       Impact factor: 2.269

5.  Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis.

Authors:  Richard T Silver; William Chow; Attilio Orazi; Stephen P Arles; Stanley J Goldsmith
Journal:  Blood       Date:  2013-07-30       Impact factor: 22.113

6.  High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

Authors:  Jean-Jacques Kiladjian; Bruno Cassinat; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Marie-Laurence Menot; Gerald Massonnet; Jean-Luc Dutel; Kamel Ghomari; Philippe Rousselot; Marie-Jose Grange; Yasmina Chait; William Vainchenker; Nathalie Parquet; Lina Abdelkader-Aljassem; Jean-François Bernard; Jean-Didier Rain; Sylvie Chevret; Christine Chomienne; Pierre Fenaux
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

7.  Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.

Authors:  Thomas Stauffer Larsen; Michael Boe Møller; Karin de Stricker; Peter Nørgaard; Jan Samuelsson; Claus Marcher; Morten T Andersen; Ole Weis Bjerrum; Hans Carl Hasselbalch
Journal:  Hematology       Date:  2009-12       Impact factor: 2.269

8.  Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.

Authors:  T S Larsen; O W Bjerrum; N Pallisgaard; M T Andersen; M B Møller; H C Hasselbalch
Journal:  Ann Hematol       Date:  2008-05-15       Impact factor: 3.673

9.  Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.

Authors:  Christian Baumgartner; Sabine Cerny-Reiterer; Karoline Sonneck; Matthias Mayerhofer; Karoline V Gleixner; Richard Fritz; Marc Kerenyi; Cedric Boudot; Fabrice Gouilleux; Jan-Wilhelm Kornfeld; Christian Sillaber; Richard Moriggl; Peter Valent
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

10.  Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Authors:  Emmanuelle Verger; Bruno Cassinat; Aurélie Chauveau; Christine Dosquet; Stephane Giraudier; Marie-Hélène Schlageter; Jean-Christophe Ianotto; Mohammed A Yassin; Nader Al-Dewik; Serge Carillo; Eric Legouffe; Valerie Ugo; Christine Chomienne; Jean-Jacques Kiladjian
Journal:  Blood       Date:  2015-10-20       Impact factor: 25.476
View more
  4 in total

1.  Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis.

Authors:  Wenjing Gu; Renchi Yang; Zhijian Xiao; Lei Zhang
Journal:  Int J Hematol       Date:  2021-06-06       Impact factor: 2.490

2.  Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values.

Authors:  Richard T Silver; Spencer Krichevsky
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

3.  A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.

Authors:  John Mascarenhas; Heidi E Kosiorek; Josef T Prchal; Alessandro Rambaldi; Dmitriy Berenzon; Abdulraheem Yacoub; Claire N Harrison; Mary Frances McMullin; Alessandro M Vannucchi; Joanne Ewing; Casey L O'Connell; Jean-Jacques Kiladjian; Adam J Mead; Elliott F Winton; David S Leibowitz; Valerio De Stefano; Murat O Arcasoy; Craig M Kessler; Rosalind Catchatourian; Damiano Rondelli; Richard T Silver; Andrea Bacigalupo; Arnon Nagler; Marina Kremyanskaya; Max F Levine; Juan E Arango Ossa; Erin McGovern; Lonette Sandy; Mohamad E Salama; Vesna Najfeld; Joseph Tripodi; Noushin Farnoud; Alexander V Penson; Rona Singer Weinberg; Leah Price; Judith D Goldberg; Tiziano Barbui; Roberto Marchioli; Gianni Tognoni; Raajit K Rampal; Ruben A Mesa; Amylou C Dueck; Ronald Hoffman
Journal:  Blood       Date:  2022-05-12       Impact factor: 25.476

4.  Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Authors:  Lucia Masarova; C Cameron Yin; Jorge E Cortes; Marina Konopleva; Gautam Borthakur; Kate J Newberry; Hagop M Kantarjian; Carlos E Bueso-Ramos; Srdan Verstovsek
Journal:  Exp Hematol Oncol       Date:  2017-11-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.